It has become increasingly clear that psoriatic disease, both of the skin and joints, can be a significant diagnostic and therapeutic challenge for the physician and a debilitating illness for the patient. Genetic and immunologic advances have increased our understanding of the pathophysiology of psoriasis and psoriatic arthritis and there is a need for practically oriented evidence based references to describe the management options open to clinicians. The speed at which developments are occurring in the field also necessitates a novel approach to keeping up with these changes in practice and the need is for a reference that that be updated regularly as the subject requires. Psoriasis is an incredibly fast-moving discipline within dermatology. Guidelines, treatment options and management all change at incredible speed. There is a requirement to provide a comprehensive reference resource to provide practical, user friendly information for the dermatology profession to aid in the decision-making process. Psoriasis is a graphical subdiscipline of medicine and therefore this will have copious illustrations. As a fast moving discipline the emphasis must be on annual updates to ensure that readers are kept up to date on the important areas of development.

Written by experts in the dermatology field, this new fourth edition of Moderate-to-Severe Psoriasis discusses the current use of biologics and other pharmacologic and phototherapy treatments for moderate-to-severe psoriasis. Illustrated with high quality color figures, this standalone text emphasizes safe and effective treatments for the psoriasis

Using a practical and problem-focused approach, this updated, full-color Third Edition of Mild-to-Moderate Psoriasis equips dermatologists, internists, family practitioners, and residents with a state-of-the-art guide to the clinical management of mild-to-moderate psoriasis.Written by an international team of key opinion leaders, this resource explores new developments in treatments for the condition and provides clinicians with up-to-date strategies for optimal patient management.

This WHO Global report on psoriasis brings the public health impact of psoriasis into focus. The report is written to help raise awareness of the range of ways that psoriasis can affect peoples' lives. It intends to empower policy-makers with practical solutions to improve the health care and social inclusion of people living with psoriasis in their populations. The report highlights that much of the suffering caused by this common and complex disease can be avoided. Improving access to early diagnosis and appropriate treatment for psoriasis requires universally accessible health-care systems that provide people-centered care for patients with complex, lifelong conditions. Governments also have a key role to play in seeking to address the unnecessary social consequences of psoriasis by the challenging the myths and behaviors that lead to the exclusion of patients from healthcare settings and daily life.

Treatments for psoriasis, besides affecting the skin, may be associated with various comorbidities (for instance, depression, psoriatic arthritis, Crohn's disease and, in severe psoriasis, metabolic syndrome and cardiovascular diseases), which often presents a therapeutic challenge to physicians.Written by renowned experts, this volume gives a comprehensive overview of psoriasis and its various comorbidities. It describes the treatment modalities for mild and moderate-to-severe psoriasis, including topical, phototherapeutic and conventional systemic treatments (e.g. acitretine, methotrexate and cyclosporine), as well as biological therapies (e.g. alefacept, efalizumab, etanercept, adalimumab and infliximab). The chapters on biological therapies focus on key safety issues. Further chapters focus on such topics as the management of childhood psoriasis and psoriasis in distinctive locations, such as the scalp, face, flexures, palm/soles and nails. Finally, future therapeutic modalities, with the focus on small molecules and potential biological therapies, are discussed.This publication will make significant reading to dermatologists and all physicians dealing with psoriasis, such as general practitioners, psychiatrists, rheumatologists, cardiologists and diabetologists.

Educational advancement in the field of psoriatic arthritis which this book will provide is consistent with GRAPPA’s aims and objectives leading to a productive synergy. GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), is recognized world wide as the leading international society for the study and promotion of awareness of psoriatic arthritis. GRAPPA is an association of leading rheumatologists, dermatologists, representatives of patient service leagues and other stakeholders focused on psoriasis and PsA.​Psoriatic Arthritis (PsA) ranks with rheumatoid arthritis and axial spondyloarthritis as one of the most prevalent inflammatory arthropathies worldwide. There is now a significant global awareness among Rheumatologists, Dermatologists, Internal Medicine Specialists, Gastroenterologists, General Practitioners, Family Practitioners, Physiotherapists, Nurse Specialists, Immunogenetics and many other Health Care Professionals with regards to the importance of psoriatic arthritis.

This book presents the evidence for the belief that psoriasis is a disease of abnormal keratinocyte proliferation induced by T cells. The latest approaches to investigating the immunopathogenesis of this disease, and a review of previous findings, are presented to give an overall picture of the current knowledge in this field. Each topic is discussed in detail, clearly illustrated and well referenced. The book should prove invaluable to clinical dermatologists, and researchers in the fields of immunology and dermatology who have an interest in skin diseases.